Drug and medical device maker Abbott Laboratories said it withdrew its request for U.S. and European approval of the potential psoriasis drug briakinumab.
Cumberland Pharmaceuticals Inc. said the Food and Drug Administration approved a new formulation of its Acetadote injection used to treat acetaminophen poisoning.
Federal health regulators are limiting a key ingredient found in Vicodin, Percocet and other prescription painkillers that have been linked to thousands of cases of liver damage each year.
The need for pharmaceutical R&D organizations to manage expanding volumes of data crucial will require a change in focus and approach.
Cancer Research UK’s drug development office has signed a Strategic Combinations Alliance with AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials.
Irked by weakened pipelines and growing pressure from patent expiries, the big pharma majors such as AstraZeneca and Pfizer found vaccines industry as safe avenue to invest and register guaranteed revenues.
Researchers report that they are the first to show in molecular detail how one gene evolved two competing functions that eventually split up – via gene duplication – to pursue their separate destinies.
Coffee, that morning elixir, may give us an early jump-start to the day, but numerous studies have shown that it also may be protective against type 2 diabetes. Yet no one has really understood why.
Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, has completed recruitment of a Phase 2 clinical trial of BC-3781 in acute bacterial skin and skin structure infections.
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced that patient dosing has commenced in a Phase 1 clinical trial of OMP-59R5 in patients with advanced solid tumor cancers.
Allos Therapeutics Inc. said that sales of the lymphoma drug Folotyn drove revenue in the fourth quarter and it will cut 13 percent of its staff. The company said it expects to report revenue of $11.7 million, which tops Wall Street estimates.
Genzyme Corp. said that it expects to report revenue growth in the fourth quarter, but the preliminary results fell short of expectations. The drugmaker also trimmed its outlook for 2011 as it continues recovering from manufacturing problems.
Watson Pharmaceuticals Inc. said Wednesday its 2010 results were about equal to its expectations. The company said its earnings will be at the midpoint of its estimated range of $3.37 to $3.45 per share.
Oregon Attorney General John Kroger has sued Johnson & Johnson and two subsidiaries, claiming consumers were exposed to defective supplies of Motrin by a delay in public disclosure of a recall.
Drugmaker Eli Lilly and Co. Inc. said a panel of federal health advisers voted against an experimental treatment designed to aid digestion in patients with cystic fibrosis and other diseases that affect the pancreas.